JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
JMP Securities Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)
JMP Securities analyst Reni Benjamin maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...
JMP Securities Raises Axon Enterprise, Inc. (AXON) Price Target to $725 on AI & Defense Demand
We recently compiled a list of the 8 AI Stocks on Investors’ Radar. In this article, we are going to take a look at where ...
Xometry appoints new CTO as Leibel departs
Mr. Leibel's departure, as stated in the company's SEC filing, is not due to any disagreements or disputes with the company's operations or practices. He will continue to serve as an employee until ...
JMP maintains Apollo stock Market Perform rating
JMP Securities maintained its Market Perform rating on Apollo Global Management (NYSE:APO) shares without setting a new price ...
Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...